A much-needed new way to inactivate GPCRs, the most common drug targets
About one-third of all drugs approved by the U.S. Food and Drug Administration target G protein-coupled receptors (GPCRs), a family of more than 800 cell-surface receptors that regulate a wide range of vital functions, including blood pressure, heart rate and immunity.
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
Protein DUSP4 prevents immune cell exhaustion in colorectal cancer
United Kingdom
-
Collapsible bicycle helmets provide less protection on average than conventional helmets, new study finds
United Kingdom
-
Alternative pathways for blood vessel growth could become targets against drug-resistant tumors
United Kingdom
-
Mother-infant bonding linked to brain connectivity before birth
United Kingdom
-
Uncovering rules for aggressive brain tumors could lead to better treatments
United Kingdom
-
Mice that watch fights come away battle-ready
United Kingdom
-
Emergency surgery verification linked to lower death rates, shorter hospital stays
United Kingdom
-
Pulse oximetry–based scoring may miss sleep apnea events in Black patients
United Kingdom